Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Agouti-signaling protein (ASIP) is a small, secreted, paracrine signaling protein encoded by the ASIP gene in humans and other mammals. It acts as a competitive antagonist or inverse agonist at certain melanocortin receptors, primarily melanocortin 1 receptor (MC1R), where it blocks the action of α-melanocyte-stimulating hormone (α-MSH), switching melanin synthesis from eumelanin (dark pigment) to pheomelanin (red/yellow)[4]. The structure comprises a C-terminal cysteine-rich domain that adopts an inhibitor cystine knot fold, critical for high affinity binding and functional antagonism at MC1R[1][2][3]. In animal models, aberrant expression of ASIP is linked to yellow coat color and obesity, highlighting a role in energy homeostasis and metabolic regulation as well as pigmentation[1][4]. ASIP is not currently a common drug target nor routinely used as a therapeutic biomarker in clinical practice.
Competitive antagonist or inverse agonist at melanocortin receptors (especially MC1R) Inhibits α-melanocyte-stimulating hormone (α-MSH)-induced activity to shift melanin production from eumelanin (dark) to pheomelanin (red/yellow)[1][2][4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Agouti-signaling protein (ASIP).